0RAG Stock Chart & Stats
€3.55
€0.05(4.00%)
At close: 4:00 PM EST
€3.55
€0.05(4.00%)
Day’s Range― - ―
52-Week Range€1.66 - €5.21
Previous CloseN/A
Volume167.00
Average Volume (3M)800.00
Market Cap
€79.44M
Enterprise Value€133.34
Total Cash (Recent Filing)€3.52M
Total Debt (Recent Filing)€3.81M
Price to Earnings (P/E)―
Beta0.29
Next Earnings
Sep 24, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.16
Shares Outstanding43,736,416
10 Day Avg. Volume552
30 Day Avg. Volume800
Financial Highlights & Ratios
PEG Ratio-1.03
Price to Book (P/B)31.58
Price to Sales (P/S)33.12
P/FCF Ratio-42.38
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-0.46
Revenue Forecast (FY)€4.66M
Bulls Say, Bears Say
Bulls Say
Positive Equity BaseMaintaining positive equity provides some residual balance-sheet support despite sustained losses. Although the cushion has narrowed, it may help the company continue advancing its development programs while it works toward improved economics and a more sustainable funding structure.
Revenue Above Earlier BaseRevenue has progressed meaningfully from earlier near-zero levels, indicating that the company has established more activity than at the start of the period. Further commercialization or development-related revenue growth could improve operating leverage if the underlying programs advance successfully.
Improved Operating Cash BurnThe reduction in operating cash outflow versus 2024 suggests some improvement in cash consumption, even though operations remain cash negative. If sustained alongside revenue development or cost discipline, this could extend financial flexibility and moderate the pace of future funding needs.
Bears Say
Severe Operating LossesVery large operating losses relative to revenue show that the current business model has not yet reached economic scale. Persistently negative margins can consume capital, constrain investment choices, and leave future financial improvement dependent on stronger revenue or a major cost-structure change.
Persistent Cash BurnOngoing negative operating and free cash flow means the company is not currently funding its activities from operations. Continued development spending without a step-change in revenue or costs increases reliance on external financing and can reduce flexibility over the next several quarters.
Rising Leverage And Eroding EquityHigher leverage combined with declining equity indicates worsening balance-sheet resilience. This reduces financial flexibility while losses continue, increases the importance of securing funding on acceptable terms, and may limit the company’s ability to absorb setbacks in its development programs.
ABIONYX Pharma SA News
0RAG FAQ
What was ABIONYX Pharma SA’s price range in the past 12 months?
ABIONYX Pharma SA lowest share price was €1.66 and its highest was €5.21 in the past 12 months.
What is ABIONYX Pharma SA’s market cap?
ABIONYX Pharma SA’s market cap is €79.44M.
When is ABIONYX Pharma SA’s upcoming earnings report date?
ABIONYX Pharma SA’s upcoming earnings report date is Sep 24, 2026 which is in 4 days.
How were ABIONYX Pharma SA’s earnings last quarter?
ABIONYX Pharma SA released its earnings results on Mar 12, 2026. The company reported -€0.091 earnings per share for the quarter.
Is ABIONYX Pharma SA overvalued?
According to Wall Street analysts ABIONYX Pharma SA’s price is currently Overvalued.
Does ABIONYX Pharma SA pay dividends?
ABIONYX Pharma SA does not currently pay dividends.
What is ABIONYX Pharma SA’s EPS estimate?
ABIONYX Pharma SA’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does ABIONYX Pharma SA have?
ABIONYX Pharma SA has 43,736,416 shares outstanding.
What happened to ABIONYX Pharma SA’s price movement after its last earnings report?
ABIONYX Pharma SA reported an EPS of -€0.091 in its last earnings report. Following the earnings report the stock price went up 1.069%.
Which hedge fund is a major shareholder of ABIONYX Pharma SA?
Currently, no hedge funds are holding shares in GB:0RAG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
ABIONYX Pharma SA
ABIONYX Pharma SA is a biotechnology company dedicated to the identification and advancement of therapies for conditions affecting the kidneys and eyes. The firm's pipeline includes CER-001, an innovative negatively-charged lipoprotein particle. This compound is designed to mimic the structural and functional attributes of pre-beta HDL, utilizing human recombinant apoA-I (a natural high-density lipoprotein protein) along with natural phospholipids like sphingomyelin and dipalmitoylphosphatidylglycerol. CER-001 is currently under development for patients recovering from acute coronary syndrome and those with familial primary hypoalphalipoproteinemia. Another key candidate, CER-002, is a specific agonist for peroxisome proliferator-activated receptor delta, targeting cardiovascular and metabolic diseases. Additionally, CER-209 is being developed as a potential treatment for metabolic liver diseases, atherosclerosis, and non-alcoholic steatohepatitis (NASH). ABIONYX maintains strategic partnerships with GTP Biologics and VBI Therapeutics Group for the bioproduction of its bio-HDL in France. Established in 2005, the company operated as Cerenis Therapeutics Holding SA before its rebranding to ABIONYX Pharma SA in August 2019. Its operations are headquartered in Balma, France.